JNJ’s Multiple Sclerosis Drug Ponvory Available From Covance Specialty Pharmacy

The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced that the FDA approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS).

PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by over a decade of cumulative clinical research.

Janssen CarePath offers a comprehensive support program that helps patients get started on PONVORY™ and stay on track. Janssen CarePath provides information on insurance coverage, potential out-of-pocket costs and treatment support, and identifies options that may help make treatment more affordable, including the Janssen CarePath Savings Program for commercially insured patients who are eligible.

For patients who are prescribed PONVORY™, the Wellness Companion Program by Janssen CarePath provides patients with one-on-one education to help them get started and continue treatment.

Covance Specialty Pharmacy, on behalf of Janssen CarePath, has been engaged to initiate therapy and schedule shipping of the drug.

Covance Drug Development (CDD) offers market access solutions, including reimbursement consulting and hotlines, patient assistance programs, health economic and outcomes research services, observational studies, real-world evidence and analytics services, and value communication services.

In 2008, Covance Market Access Services (CMA) founded Covance Specialty Pharmacy LLC (CSP) to expand its service offering to include distribution of free goods and other pharmacy services.

CSP dispenses free product through direct shipments to patients’ homes or their physicians’ offices. Covance has always been an industry leader in resolving reimbursement challenges and eliminating barriers to product utilization. 


 Takeaway: Ponvory joins a crowded Sphingosine 1-phosphate (S1P) receptor modulators market that includes Biogen, Sanofi, Novartis and BMS